PARP1 and neoplasm: Several PARP inhibitors are approved for the treatment of ovarian, breast, prostate, and pancreatic cancers, including for patients with deleterious/suspected deleterious BRCA mutations (BRCAmut) and/or tumours with HRD [6–9].